Search research articles
Contact Us
Filters
Showing results (931-940 of 1,171) with videos related to
Page
of 118
Sort By:
British Journal of Cancer
|
September 1, 2017
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
Monica M Mita, Alain C Mita, Jennifer L Moseley, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 16, 2025
Molecular Phenotyping of Sepsis and Differential Response to Fluid Resuscitation
Elizabeth Kiernan, Leila R Zelnick, Ayesha Khader, et al.
The Journal of Clinical Investigation
|
July 3, 2025
Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma
Jithma P Abeykoon, Shuhei Asada, Guangli Zhu, et al.
Cancer Research Communications
|
June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2025
A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer
Filipa Lynce, Noah Graham, Bose S Kochupurakkal, et al.
Molecular Cancer Therapeutics
|
April 15, 2018
RAS-MAPK Reactivation Facilitates Acquired Resistance in <i>FGFR1</i>-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade
Bruno Bockorny, Maria Rusan, Wankun Chen, et al.
Investigational New Drugs
|
April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
March 1, 2023
Na/K-ATPase signaling tonically inhibits sodium reabsorption in the renal proximal tubule
Shreya T Mukherji, Luca Brambilla, Kailey B Stuart, et al.
Molecular Cancer Therapeutics
|
February 13, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
Elizabeth Pan, Wanling Xie, Archana Ajmera, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
Ana C Garrido-Castro, Noah Graham, Lestat R Ali, et al.
Page
of 118
Search research articles
Search
Showing results (931-940 of 1,171) with videos related to
Sort By:
Page
of 118
British Journal of Cancer
|
September 1, 2017
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
Monica M Mita, Alain C Mita, Jennifer L Moseley, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 16, 2025
Molecular Phenotyping of Sepsis and Differential Response to Fluid Resuscitation
Elizabeth Kiernan, Leila R Zelnick, Ayesha Khader, et al.
The Journal of Clinical Investigation
|
July 3, 2025
Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma
Jithma P Abeykoon, Shuhei Asada, Guangli Zhu, et al.
Cancer Research Communications
|
June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2025
A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer
Filipa Lynce, Noah Graham, Bose S Kochupurakkal, et al.
Molecular Cancer Therapeutics
|
April 15, 2018
RAS-MAPK Reactivation Facilitates Acquired Resistance in <i>FGFR1</i>-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade
Bruno Bockorny, Maria Rusan, Wankun Chen, et al.
Investigational New Drugs
|
April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
March 1, 2023
Na/K-ATPase signaling tonically inhibits sodium reabsorption in the renal proximal tubule
Shreya T Mukherji, Luca Brambilla, Kailey B Stuart, et al.
Molecular Cancer Therapeutics
|
February 13, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
Elizabeth Pan, Wanling Xie, Archana Ajmera, et al.
Journal for Immunotherapy of Cancer
|
February 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
Ana C Garrido-Castro, Noah Graham, Lestat R Ali, et al.
Page
of 118